# US 2021/0275612 A1 · Method for alleviating inflammation-related disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275612 A1
- Document ID: US20210275612A1
- Status: Published application
- Kind: A1
- Application number: 17/191,766
- Filed: 2021-03-04
- Published: 2021-09-09
- Earliest claimed: 2020-03-09
- Assignees: Glac Biotech Co., Ltd.
- Applicants: Glac Biotech Co., Ltd.
- Inventors: Cheng-Ruei LIU; Yi-Wei KUO; Hsieh-Hsun HO
- Web page: https://patentgrep.com/patent/US20210275612A1

## CPC

- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A23L 33/40: {Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula}
- A61K 35/745: Bifidobacteria
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23V 2400/169: Plantarum
- A23V 2400/531: Lactis
- A23V 2400/533: Longum
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

Disclosed herein is a method for alleviating an inflammation-related disorder, which includes administering to a subject in need thereof a composition containing a culture of at least one lactic acid bacterial strain. The at least one lactic acid bacterial strain is selected from the group consisting of Lactobacillus plantarum LPL28 which is deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 17954, Bifidobacterium animalis subsp. lactis CP-9 which is deposited at the China Center for Type Culture Collection (CCTCC) under an accession number CCTCC M 2014588, and Bifidobacterium longum subsp. longum OLP-01 which is deposited at the CGMCC under an accession number CGMCC 17345.

## Claims

### Claim 1

A method for alleviating an inflammation-related disorder, comprising administering to a subject in need thereof a composition containing a culture of at least one lactic acid bacterial strain,
wherein the at least one lactic acid bacterial strain is selected from the group consisting of Lactobacillus plantarum LPL28 which is deposited at the China General Microbiological Culture Collection Center (CGMCC) under an accession number CGMCC 17954, Bifidobacterium animalis subsp. lactis CP-9 which is deposited at the China Center for Type Culture Collection (CCTCC) under an accession number CCTCC M 2014588, and Bifidobacterium longum subsp. longum OLP-01 which is deposited at the CGMCC under an accession number CGMCC 17345.

### Claim 2 (depends on 1)

The method as claimed in claim 1, wherein the inflammation-related disorder is selected from the group consisting of allergy, organ transplant rejection, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, multiple sclerosis, inflammatory bowel disease, Graves' disease, celiac disease, type 1 diabetes mellitus, and combinations thereof.

### Claim 3 (depends on 1)

The method as claimed in claim 1, wherein the culture is a liquid culture.

### Claim 4 (depends on 3)

The method as claimed in claim 3, wherein the liquid culture is substantially free of cells.

### Claim 5 (depends on 1)

The method as claimed in claim 1, wherein the composition is formulated as a food product.

### Claim 6 (depends on 1)

The method as claimed in claim 1, wherein the composition is formulated as a pharmaceutical composition.

### Claim 7 (depends on 6)

The method as claimed in claim 6, wherein the pharmaceutical composition is in a dosage form for oral administration.

### Claim 8 (depends on 6)

The method as claimed in claim 6, wherein the pharmaceutical composition is in a dosage form for topical administration.

### Claim 9 (depends on 1)

The method as claimed in claim 1, wherein the composition further comprises a probiotic microorganism selected from the group consisting of Lactobacillus acidophilus TYCA06 (BCRC 910813), Lactobacillus reuteri GL-104 (BCRC 910404), Lactobacillus salivarius subsp. salicinius AP-32 (BCRC 910437), Lactobacillus rhamnosus F-1 (BCRC 910469), Bifidobacterium longum subsp. infantis BLI-02 (BCRC 910812), and combinations thereof.